Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma

A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Frontiers in immunology Ročník 14; s. 1334408
Hlavní autoři:	Wang, Duo, Huang, Liuying, Qian, Danqi, Cao, Yulin, Wu, Xiaohan, Xu, Peiwen, Ming, Liang, Tang, Junhui, Huang, Zhaohui, Yin, Yuan, Zhou, Leyuan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media SA 08.01.2024 Frontiers Media S.A
Témata:	Adenocarcinoma Adenocarcinoma - radiotherapy Adenocarcinoma of Lung - radiotherapy Alcohol Animals Antibodies Antigens Antitumor activity Cancer therapies CD8 antigen Dendritic cells Disease Models, Animal Humans Immunology Immunotherapy low dose radiotherapy Lung cancer Lung Neoplasms - radiotherapy Lymphocytes T Maturation Medical prognosis Medical research Mice Optimization techniques Patients PD-1 protein Prognosis Proto-Oncogene Proteins p21(ras) - genetics Radiation therapy Risk factors Tertiary Lymphoid Structures tumor microenvironment Tumors lung cancer low dose radiotherapy tumor microenvironment immunotherapy tertiary lymphoid structures
ISSN:	1664-3224, 1664-3224
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy. Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs. TLS+, TLS , TLS+GC+ and CD8 within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs. We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.
AbstractList	PurposeA tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.MethodsTissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.ResultsTLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.ConclusionWe successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect. A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.PurposeA tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.MethodsTissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.TLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.ResultsTLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.ConclusionWe successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect. A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy. Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs. TLS+, TLS , TLS+GC+ and CD8 within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs. We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.
Author	Cao, Yulin Ming, Liang Qian, Danqi Zhou, Leyuan Wang, Duo Xu, Peiwen Wu, Xiaohan Huang, Liuying Tang, Junhui Yin, Yuan Huang, Zhaohui
AuthorAffiliation	2 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University , Wuxi , China 4 State Key Laboratory of Radiation Medicine and Protection, Soochow University , Suzhou , China 3 Department of Radiation Oncology, Dushu Lake Hospital Affiliated to Soochow University , Suzhou , China 1 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University , Wuxi , China
AuthorAffiliation_xml	– name: 3 Department of Radiation Oncology, Dushu Lake Hospital Affiliated to Soochow University , Suzhou , China – name: 2 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University , Wuxi , China – name: 1 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University , Wuxi , China – name: 4 State Key Laboratory of Radiation Medicine and Protection, Soochow University , Suzhou , China
Author_xml	– sequence: 1 givenname: Duo surname: Wang fullname: Wang, Duo – sequence: 2 givenname: Liuying surname: Huang fullname: Huang, Liuying – sequence: 3 givenname: Danqi surname: Qian fullname: Qian, Danqi – sequence: 4 givenname: Yulin surname: Cao fullname: Cao, Yulin – sequence: 5 givenname: Xiaohan surname: Wu fullname: Wu, Xiaohan – sequence: 6 givenname: Peiwen surname: Xu fullname: Xu, Peiwen – sequence: 7 givenname: Liang surname: Ming fullname: Ming, Liang – sequence: 8 givenname: Junhui surname: Tang fullname: Tang, Junhui – sequence: 9 givenname: Zhaohui surname: Huang fullname: Huang, Zhaohui – sequence: 10 givenname: Yuan surname: Yin fullname: Yin, Yuan – sequence: 11 givenname: Leyuan surname: Zhou fullname: Zhou, Leyuan
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38259481$$D View this record in MEDLINE/PubMed
BookMark	eNp9kktv3CAUha0qVZOm-QNdVJa66cZT4GIbVlUV9RFppG7aNcI8ZhjZ4AJuNP--zKNRkkXZgC7fPToXzuvqwgdvquotRisAxj9aN03LiiACKwxAKWIvqivcdbQBQujFo_NldZPSDpVFOQC0r6pLYKTllOGrSq3DfaNDMnWU2oW8NVHO-3qOYQrZpLoUahviJLMLvg62ziZmJ-O-HvfTvA1O1ynHReUlFtr5elz8ppba-KBkVM6HSb6pXlo5JnNz3q-rX1-__Lz93qx_fLu7_bxuFOV9bnCPodPADVME9ECZVZgz3KIBa2QHjBW0sgxBtCbtgDQjllGLwWLM2qFFcF3dnXR1kDsxRzcVnyJIJ46FEDdCFvNqNEJZLnlrYcBc0p7rgZkWAzFSk45Cq4rWp5PWvAyT0cr4HOX4RPTpjXdbsQl_BEYMIY5YUfhwVojh92JSFpNLyoyj9CYsSRCOe9YBQ7Sg75-hu7BEX95KAOkZ6Q-mCvXusaUHL_8-swDkBKgYUorGPiAYiUNoxDE04hAacQ5NaWLPmpTLx98uY7nxf61_AbN9yTg
CitedBy_id	crossref_primary_10_1016_j_tranon_2025_102326 crossref_primary_10_1186_s12943_024_01980_6 crossref_primary_10_1016_j_lfs_2025_123800 crossref_primary_10_1017_erm_2024_27 crossref_primary_10_1007_s11864_025_01342_4 crossref_primary_10_1038_s41392_024_01947_5 crossref_primary_10_1136_jitc_2025_011617 crossref_primary_10_1186_s12935_025_03668_3 crossref_primary_10_1038_s41467_025_59865_1 crossref_primary_10_1111_imm_70027 crossref_primary_10_1186_s12885_025_14119_7 crossref_primary_10_1111_imr_70046
Cites_doi	10.1016/s1470-2045(20)30140-6 10.1158/1078-0432.ccr-21-1130 10.1126/sciadv.aav2437 10.4161/onci.28976 10.1136/jitc-2022-005539 10.3389/fonc.2012.00120 10.1126/science.abf9419 10.1016/j.canrad.2021.06.002 10.1177/0300060519892382 10.1158/2159-8290.cd-21-0003 10.1183/13993003.04352-2020 10.1016/j.ccr.2013.09.014 10.1136/jitc-2020-000537 10.1016/j.ijrobp.2020.07.1741 10.1038/s41423-020-0457-0 10.1016/j.immuni.2023.08.009 10.1016/j.immuni.2021.12.007 10.1016/j.tranon.2023.101710 10.3389/fimmu.2019.00317 10.1016/j.jcmgh.2021.06.023 10.1016/s0140-6736(21)00312-3 10.1007/s00018-017-2686-7 10.1002/ijc.30235 10.1200/jco.2011.37.8539 10.1016/s0304-3835(03)00309-4 10.1080/2162402x.2017.1378844 10.3322/caac.21708 10.1158/1078-0432.ccr-15-2762 10.1038/s41586-019-1922-8 10.1016/j.apsb.2021.03.027 10.1038/s41467-022-29701-x 10.1158/0008-5472.can-17-1987 10.1200/jco.2020.38.15_suppl.e21097 10.1158/2159-8290.cd-20-0962 10.1038/s41598-018-30417-6 10.1016/j.immuni.2015.08.006 10.1056/nejmoa1507643 10.1016/j.ymthe.2018.08.002 10.1038/s12276-019-0356-6 10.1038/s41586-019-1914-8 10.1080/2162402x.2021.1900635 10.1038/bjc.2015.145 10.1097/jto.0000000000000678 10.1016/j.ijrobp.2021.07.270 10.1158/1078-0432.ccr-13-2590
ContentType	Journal Article
Copyright	Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou
Copyright_xml	– notice: Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 5PM DOA
DOI	10.3389/fimmu.2023.1334408
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	1664-3224
ExternalDocumentID	oai_doaj_org_article_cf9a95f3b19a479db8e5132ead26435c PMC10800908 38259481 10_3389_fimmu_2023_1334408
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM ACXDI CGR CUY CVF ECM EIF IAO IEA IHR IHW IPNFZ NPM RIG 3V. 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GNUQQ HCIFZ K9. LK8 M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 5PM
ID	FETCH-LOGICAL-c497t-17136d39e8c23db48fc198150b1d0fb11c35a0042dd25b0d82f84f13f1185b503
IEDL.DBID	8C1
ISICitedReferencesCount	16
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001147860400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1664-3224
IngestDate	Fri Oct 03 12:43:23 EDT 2025 Thu Aug 21 18:36:20 EDT 2025 Fri Sep 05 10:39:08 EDT 2025 Tue Dec 02 16:04:03 EST 2025 Wed Feb 19 02:07:23 EST 2025 Tue Nov 18 21:54:06 EST 2025 Sat Nov 29 05:40:43 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	lung cancer low dose radiotherapy tumor microenvironment immunotherapy tertiary lymphoid structures
Language	English
License	Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c497t-17136d39e8c23db48fc198150b1d0fb11c35a0042dd25b0d82f84f13f1185b503
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Edited by: Tiezheng Hou, University College London, United Kingdom Shisuo Du, Fudan University, China Minghui Cao, University of California, San Diego, United States Reviewed by: Lei Dong, Nanjing University, China Xu Zhang, Jiangsu University, China
OpenAccessLink	https://www.proquest.com/docview/3278272643?pq-origsite=%requestingapplication%
PMID	38259481
PQID	3278272643
PQPubID	7426807
ParticipantIDs	doaj_primary_oai_doaj_org_article_cf9a95f3b19a479db8e5132ead26435c pubmedcentral_primary_oai_pubmedcentral_nih_gov_10800908 proquest_miscellaneous_2917863804 proquest_journals_3278272643 pubmed_primary_38259481 crossref_primary_10_3389_fimmu_2023_1334408 crossref_citationtrail_10_3389_fimmu_2023_1334408
PublicationCentury	2000
PublicationDate	2024-01-08
PublicationDateYYYYMMDD	2024-01-08
PublicationDate_xml	– month: 01 year: 2024 text: 2024-01-08 day: 08
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Lausanne
PublicationTitle	Frontiers in immunology
PublicationTitleAlternate	Front Immunol
PublicationYear	2024
Publisher	Frontiers Media SA Frontiers Media S.A
Publisher_xml	– name: Frontiers Media SA – name: Frontiers Media S.A
References	Xu (B5) 2020; 52 Wolf (B38) 2023; 56 Kroeger (B43) 2016; 22 Abbassi (B19) 2021; 26 Cabrita (B14) 2020; 577 Klug (B24) 2013; 24 Yang (B21) 2016; 139 Thai (B2) 2021; 398 Goc (B8) 2014; 3 Liu (B22) 2019; 10 Fleig (B16) 2022; 13 Zhou (B28) 2020; 38 Joshi (B36) 2015; 43 Barsoumian (B25) 2020; 8 Schumacher (B6) 2022; 375 Yin (B27) 2020; 108 Sun (B4) 2018; 26 Gunderson A (B44) 2021; 10 Posch (B10) 2018; 7 Ostroumov (B35) 2017; 75 Hiraoka (B12) 2022; 112 Delvecchio (B17) 2021; 12 Helmink (B13) 2020; 577 Munoz-Erazo (B41) 2020; 17 Sanmamed (B30) 2021; 11 Gao (B18) 2023; 35 He (B26) 2021; 111 Siegel (B1) 2022; 72 Asamura (B3) 2015; 10 Lauss (B7) 2022; 28 Xie (B31) 2021; 11 Chaurio (B15) 2022; 55 Rödel (B23) 2012; 2 Borghaei (B39) 2015; 373 He (B45) 2023; 11 Miller (B37) 2003; 198 Siliņa (B33) 2018; 78 Di Caro (B42) 2014; 20 Curtis (B9) 2021; 57 Pei (B20) 2019; 48 Shu (B40) 2020; 21 Herrera (B29) 2022; 12 Azimi (B11) 2012; 30 Chen (B32) 2018; 8 Tu (B34) 2019; 5
References_xml	– volume: 21 year: 2020 ident: B40 article-title: Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/s1470-2045(20)30140-6 – volume: 28 year: 2022 ident: B7 article-title: B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-21-1130 – volume: 5 year: 2019 ident: B34 article-title: Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy publication-title: Sci Adv doi: 10.1126/sciadv.aav2437 – volume: 3 year: 2014 ident: B8 article-title: Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses publication-title: OncoImmunology doi: 10.4161/onci.28976 – volume: 11 year: 2023 ident: B45 article-title: Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer publication-title: J ImmunoTher Cancer doi: 10.1136/jitc-2022-005539 – volume: 2 year: 2012 ident: B23 article-title: Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation publication-title: Front Oncol doi: 10.3389/fonc.2012.00120 – volume: 375 year: 2022 ident: B6 article-title: Tertiary lymphoid structures in cancer publication-title: Science doi: 10.1126/science.abf9419 – volume: 26 year: 2021 ident: B19 article-title: Radiation dose to the low axilla in patients treated for early-stage breast cancer by locoregional intensity-modulated radiotherapy (IMRT) publication-title: Cancer/Radiothérapie doi: 10.1016/j.canrad.2021.06.002 – volume: 48 year: 2019 ident: B20 article-title: A retrospective cohort study of low-dose intensity-modulated radiotherapy for unresectable liver metastases publication-title: J Int Med Res doi: 10.1177/0300060519892382 – volume: 12 year: 2022 ident: B29 article-title: Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy publication-title: Cancer Discov doi: 10.1158/2159-8290.cd-21-0003 – volume: 57 year: 2021 ident: B9 article-title: Wouldn’t you like to know: are tertiary lymphoid structures necessary for lung defence publication-title: Eur Respir J doi: 10.1183/13993003.04352-2020 – volume: 24 start-page: 589 year: 2013 ident: B24 article-title: Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy publication-title: Cancer Cell doi: 10.1016/j.ccr.2013.09.014 – volume: 8 year: 2020 ident: B25 article-title: Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma publication-title: J ImmunoTher Cancer doi: 10.1136/jitc-2020-000537 – volume: 108 year: 2020 ident: B27 article-title: Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients publication-title: Int J Radiat Oncol • Biol • Phys doi: 10.1016/j.ijrobp.2020.07.1741 – volume: 17 year: 2020 ident: B41 article-title: Tertiary lymphoid structures in cancer - considerations for patient prognosis publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-0457-0 – volume: 56 year: 2023 ident: B38 article-title: Tertiary lymphoid structures and B cells: An intratumoral immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2023.08.009 – volume: 55 start-page: 115 year: 2022 ident: B15 article-title: TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures publication-title: Immunity doi: 10.1016/j.immuni.2021.12.007 – volume: 35 year: 2023 ident: B18 article-title: Low-dose radiotherapy effects the progression of anti-tumor response publication-title: Trans Oncol doi: 10.1016/j.tranon.2023.101710 – volume: 10 year: 2019 ident: B22 article-title: Low-dose total body irradiation can enhance systemic immune related response induced by hypo-fractionated radiation publication-title: Front Immunol doi: 10.3389/fimmu.2019.00317 – volume: 12 year: 2021 ident: B17 article-title: Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice publication-title: Cell Mol Gastroenterol Hepatol doi: 10.1016/j.jcmgh.2021.06.023 – volume: 398 year: 2021 ident: B2 article-title: Lung cancer publication-title: Lancet doi: 10.1016/s0140-6736(21)00312-3 – volume: 75 start-page: 689 year: 2017 ident: B35 article-title: CD4 and CD8 T lymphocyte interplay in controlling tumor growth publication-title: Cell Mol Life Sci doi: 10.1007/s00018-017-2686-7 – volume: 139 year: 2016 ident: B21 article-title: Low-dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics publication-title: Int J Cancer doi: 10.1002/ijc.30235 – volume: 30 year: 2012 ident: B11 article-title: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma publication-title: J Clin Oncol doi: 10.1200/jco.2011.37.8539 – volume: 198 year: 2003 ident: B37 article-title: Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections publication-title: Cancer Lett doi: 10.1016/s0304-3835(03)00309-4 – volume: 7 year: 2018 ident: B10 article-title: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer publication-title: OncoImmunology doi: 10.1080/2162402x.2017.1378844 – volume: 72 start-page: 7 year: 2022 ident: B1 article-title: Cancer statistics, 2022 publication-title: CA: A Cancer J Clin doi: 10.3322/caac.21708 – volume: 22 year: 2016 ident: B43 article-title: Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-15-2762 – volume: 577 year: 2020 ident: B13 article-title: B cells and tertiary lymphoid structures promote immunotherapy response publication-title: Nature doi: 10.1038/s41586-019-1922-8 – volume: 11 year: 2021 ident: B31 article-title: Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2021.03.027 – volume: 13 start-page: 2022 year: 2022 ident: B16 article-title: Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures publication-title: Nat Commun doi: 10.1038/s41467-022-29701-x – volume: 78 year: 2018 ident: B33 article-title: Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma publication-title: Cancer Res doi: 10.1158/0008-5472.can-17-1987 – volume: 38 year: 2020 ident: B28 article-title: Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer publication-title: J Clin Oncol doi: 10.1200/jco.2020.38.15_suppl.e21097 – volume: 11 year: 2021 ident: B30 article-title: A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy publication-title: Cancer Discov doi: 10.1158/2159-8290.cd-20-0962 – volume: 8 start-page: 11934 year: 2018 ident: B32 article-title: Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance publication-title: Sci Rep doi: 10.1038/s41598-018-30417-6 – volume: 43 year: 2015 ident: B36 article-title: Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses publication-title: Immunity doi: 10.1016/j.immuni.2015.08.006 – volume: 373 year: 2015 ident: B39 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/nejmoa1507643 – volume: 26 year: 2018 ident: B4 article-title: Disruption of chromosomal architecture of cox2 locus sensitizes lung cancer cells to radiotherapy publication-title: Mol Ther doi: 10.1016/j.ymthe.2018.08.002 – volume: 52 start-page: 41 year: 2020 ident: B5 article-title: The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small-cell lung cancer publication-title: Exp Mol Med doi: 10.1038/s12276-019-0356-6 – volume: 577 year: 2020 ident: B14 article-title: Tertiary lymphoid structures improve immunotherapy and survival in melanoma publication-title: Nature doi: 10.1038/s41586-019-1914-8 – volume: 10 year: 2021 ident: B44 article-title: Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer publication-title: OncoImmunology doi: 10.1080/2162402x.2021.1900635 – volume: 112 year: 2022 ident: B12 article-title: Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer publication-title: Br J Cancer doi: 10.1038/bjc.2015.145 – volume: 10 year: 2015 ident: B3 article-title: The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1097/jto.0000000000000678 – volume: 111 year: 2021 ident: B26 article-title: Phase II trial of high-dose radiotherapy vs. Low-dose radiation, demonstrating low-dose mediated immune-cell infiltration publication-title: Int J Radiat Oncol • Biol • Phys doi: 10.1016/j.ijrobp.2021.07.270 – volume: 20 year: 2014 ident: B42 article-title: Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-13-2590
SSID	ssj0000493335
Score	2.4537911
Snippet	A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to... PurposeA tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	1334408
SubjectTerms	Adenocarcinoma Adenocarcinoma - radiotherapy Adenocarcinoma of Lung - radiotherapy Alcohol Animals Antibodies Antigens Antitumor activity Cancer therapies CD8 antigen Dendritic cells Disease Models, Animal Humans Immunology Immunotherapy low dose radiotherapy Lung cancer Lung Neoplasms - radiotherapy Lymphocytes T Maturation Medical prognosis Medical research Mice Optimization techniques Patients PD-1 protein Prognosis Proto-Oncogene Proteins p21(ras) - genetics Radiation therapy Risk factors Tertiary Lymphoid Structures tumor microenvironment Tumors
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yKHgRv62uEsGbdLdpknZyVHHxsCweFPYW8omV99rldZ_y_nsnTbe8J6IXr0kK6cxkZn7t5DeEvAEThIHgS-nTlRzfsFK5VpaVhyY2tQPwE4nreXtxAZeX6vNeq69UE5bpgbPgTl1URsnILVNGtMpbCBIRFAoAQzmXLnlfzHr2wNT3nPdyzmW-JYMoTJ3Gbr3enqRm4ScIy1Kf5YNINBH2_ynL_L1Yci_6nN0n9-a0kb7L231AboX-IbmTG0nuHhF3Pvws_TAGujG-my9V7ejVVGsXRooDdLmmSIdIUyVAZzY7utqhOofO00wku0X0TbuertAHUIM-CUPdxnX9sDaPydezj18-fCrn9gmlE6q9Lhniz8ZzFcDV3FsB0TEFmABa5qtoGXNcmnRova-lReXUEURkPCLmkFZW_Ak56oc-PCNU2lCD9dyADaKuIrTGVMrIWnDvbWgKwm5Eqd3MLZ5aXKw0Yowkfj2JXyfx61n8BXm7PHOVmTX-uvp90tCyMrFiTwNoK3q2Ff0vWynI8Y1-9XxUR81rTJLatKAgr5dpPGTpz4npw7AddY2gFtBTVaIgT7M5LDvhiLET5U1B4MBQDrZ6ONN33yYi71TfWakKnv-Pl3tB7qLAxPR5CI7JEVpNeEluux_X3bh5NR2PXxtUF8g priority: 102 providerName: Directory of Open Access Journals
Title	Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma
URI	https://www.ncbi.nlm.nih.gov/pubmed/38259481 https://www.proquest.com/docview/3278272643 https://www.proquest.com/docview/2917863804 https://pubmed.ncbi.nlm.nih.gov/PMC10800908 https://doaj.org/article/cf9a95f3b19a479db8e5132ead26435c
Volume	14
WOSCitedRecordID	wos001147860400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLfYBhIXvmGBURmJG8oWx3FjnxCbOoE0qgqBVE6RP0ekNumSFdQLfzvPThooQrtw8cFOJCu_9-Hfy_N7CL3m0maSWxMz46_kmDGJhc5ZnBg-duNUc25CEdeLfDrl87mY9QG3tk-r3NrEYKhNrX2M_ISm4MtycN_07eoq9l2j_N_VvoXGHjogaZJ5xeRnZIixwOmXUsq6uzLAxcSJK5fL9bFvGX4M5Mx3W97xR6Fs_7_Omn-nTP7hg87v_-_uH6B7_ekTv-vE5SG6ZatH6E7Xj3LzGOmL-kds6tbiRpqyv5u1wauQsmdbDBN4uO2Ia4d9QkEpmw1ebEAq6tLgrh7tGkg8Liu8AFOCJZg28JiNLqt6KZ-gL-eTz2fv474LQ6wzkV_HBGjs2FBhuU6pURl3mggO50hFTOIUIZoy6XXfmJQpwDh1PHOEOqAuTLGEPkX7VV3ZQ4SZsilXhkqubJYmjudSJkKyNKPGKDuOENliUei-RLnvlLEogKp4_IqAX-HxK3r8IvRmeGfVFei48elTD_HwpC-uHSbq5rLodbXQTkjBHFVEyCwXRnHLgLSDznkAmY7Q0Rbkotf4tviNcIReDcugq_4HjKxsvW6LFLgxB4OXZBF61snTsBMKVN1XzokQ35G0na3urlTlt1AP3KeJJiLhz2_e1wt0Fz5FFuJH_AjtgzzYl-i2_n5dts0I7eXzPIx8FLRohA5OJ9PZp1EIU4x8UuzMjz8nsDL78HH29RfN9S1B
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKAcGFfQkUMBKcUNrEjif2ASG2qlWHEYcizc31CpFmkiHpUM2f4jfynGQCg1BvPXCNncixP3_vPfstCL3gymWKOxszG0Jy7CiNhclZnFg-8iNiOLdtEtdxPpnw6VR83kI_17Ewwa1yzYktUdvKhDPyPUpAluUgvumbxfc4VI0Kt6vrEhodLI7c6gxMtub14QdY35eE7H88fn8Q91UFYpOJ_DROwSwbWSocN4RanXFvwPAGvUinNvE6TQ1lKmDZWsI0jJl4nvmUelDFmWYJhe9eQpeBx_PgQpZP8-FMB7RtSinrYnPA9hN7vpjPl7uhRPkuGIOhuvOG_GvLBPxLt_3bRfMPmbd_83-brVvoRq9d47fddriNtlx5B13t6m2u7iIzrs5iWzUO18oWfezZCi9al0TXYHiAh2hOXHkcHCYKVa_wbAWorwqLu3y7yxp6FyWeAVViBdQNGkFtirKaq3voy4X84X20XVale4gw045wbani2mUk8TxXKhGKkYxaq90oQul67aXpU7CHSiAzCaZYwIts8SIDXmSPlwi9Gt5ZdAlIzu39LkBq6BmSh7cPqvqr7LlIGi-UYJ7qVKgsF1Zzx1JKgFMCYJiJ0M4aVLJntEb-RlSEng_NwEXhgkmVrlo2koDtz4HQkyxCDzr8DiOhnLSZgSLEN5C9MdTNlrL41uY7D26wiUj4o_PH9QxdOzj-NJbjw8nRY3QdpiVrz8r4DtoGbLgn6Ir5cVo09dN212J0ctHA_wWiC3_z
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-dose+radiotherapy+promotes+the+formation+of+tertiary+lymphoid+structures+in+lung+adenocarcinoma&rft.jtitle=Frontiers+in+immunology&rft.au=Wang%2C+Duo&rft.au=Huang%2C+Liuying&rft.au=Qian%2C+Danqi&rft.au=Cao%2C+Yulin&rft.date=2024-01-08&rft.eissn=1664-3224&rft.volume=14&rft.spage=1334408&rft_id=info:doi/10.3389%2Ffimmu.2023.1334408&rft_id=info%3Apmid%2F38259481&rft.externalDocID=38259481
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon